New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.

[1]  A. Skrahin,et al.  Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. , 2014, The Lancet. Respiratory medicine.

[2]  S. Cole,et al.  Tuberculosis drug discovery in the post-post-genomic era , 2014, EMBO molecular medicine.

[3]  R. Reves,et al.  Persistent latent tuberculosis reactivation risk in United States immigrants. , 2014, American journal of respiratory and critical care medicine.

[4]  Julian Parkhill,et al.  Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study , 2013, The Lancet. Respiratory medicine.

[5]  Chi‐Huey Wong,et al.  Lipoamide channel-binding sulfonamides selectively inhibit mycobacterial lipoamide dehydrogenase. , 2013, Biochemistry.

[6]  L. Smeeth,et al.  Dangers of non-specific composite outcome measures in clinical trials , 2013, BMJ.

[7]  F. Giannoni,et al.  Targeting Dormant Bacilli to Fight Tuberculosis , 2013, Mediterranean journal of hematology and infectious diseases.

[8]  M. Parmar,et al.  A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis , 2013, BMC Medical Research Methodology.

[9]  M. Nsereko,et al.  Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  Terence Chorba,et al.  Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. , 2013, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[11]  W. Bishai,et al.  Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis , 2013, Antimicrobial Agents and Chemotherapy.

[12]  J. Pasipanodya,et al.  Thioridazine Pharmacokinetic-Pharmacodynamic Parameters “Wobble” during Treatment of Tuberculosis: a Theoretical Basis for Shorter-Duration Curative Monotherapy with Congeners , 2013, Antimicrobial Agents and Chemotherapy.

[13]  W. Bishai,et al.  Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. , 2013, American journal of respiratory and critical care medicine.

[14]  G. Kaplan,et al.  Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection , 2013, PloS one.

[15]  R. Wallis,et al.  Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model , 2013, PloS one.

[16]  Se Yeon Kim,et al.  Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis , 2013, Nature Medicine.

[17]  W. Bishai,et al.  Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. , 2013, The Journal of infectious diseases.

[18]  A. Diacon,et al.  Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. , 2013, The Lancet. Respiratory medicine.

[19]  P. Cardona,et al.  Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. , 2013, The Journal of infectious diseases.

[20]  P. Venkatesan,et al.  Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis Patients , 2013, PloS one.

[21]  M. Behr,et al.  Tuberculosis vaccine trials , 2013, The Lancet.

[22]  G. Davies,et al.  Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). , 2013, The Cochrane database of systematic reviews.

[23]  Alimuddin Zumla,et al.  Drug-resistant tuberculosis: time for visionary political leadership. , 2013, The Lancet. Infectious diseases.

[24]  S. Mwaigwisya,et al.  Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay , 2013, BMJ Open.

[25]  K. Fielding,et al.  An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse , 2013, PloS one.

[26]  Alimuddin Zumla,et al.  Advances in the development of new tuberculosis drugs and treatment regimens , 2013, Nature Reviews Drug Discovery.

[27]  A. Diacon,et al.  Direct Comparison of Xpert MTB/RIF Assay with Liquid and Solid Mycobacterial Culture for Quantification of Early Bactericidal Activity , 2013, Journal of Clinical Microbiology.

[28]  Alimuddin Zumla,et al.  Systems level immune response analysis and personalized medicine , 2013, Expert review of clinical immunology.

[29]  Alimuddin Zumla,et al.  Tuberculosis 2013 : 2 Tuberculosis biomarkers discovery : developments , needs , and challenges , 2013 .

[30]  Marieke J. van der Werf,et al.  Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination , 2013, European Respiratory Journal.

[31]  D. van Soolingen,et al.  The added effect of thioridazine in the treatment of drug-resistant tuberculosis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[32]  K. Floyd,et al.  Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF , 2012, European Respiratory Journal.

[33]  T. Holtz,et al.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes , 2012, European Respiratory Journal.

[34]  Sonya S. Shin,et al.  Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis , 2012, European Respiratory Journal.

[35]  V. Leimane,et al.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis , 2012, European Respiratory Journal.

[36]  Christopher B. Cooper,et al.  Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. , 2012, Journal of medicinal chemistry.

[37]  A. Diacon,et al.  14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial , 2012, The Lancet.

[38]  S. Cole,et al.  In Vitro Combination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[39]  W. Manosuthi,et al.  Time to Initiate Antiretroviral Therapy Between 4 Weeks and 12 Weeks of Tuberculosis Treatment in HIV-Infected Patients: Results From the TIME Study , 2012, Journal of acquired immune deficiency syndromes.

[40]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[41]  C. Sismanidis,et al.  A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project , 2012, Trials.

[42]  M. Hoelscher,et al.  Innovative trial designs are practical solutions for improving the treatment of tuberculosis. , 2012, The Journal of infectious diseases.

[43]  R. Atun,et al.  Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs. , 2012, The Journal of infectious diseases.

[44]  J. O’Grady,et al.  Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. , 2012, The Journal of infectious diseases.

[45]  David Beer,et al.  A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating Mycobacterium tuberculosis , 2012, ACS chemical biology.

[46]  T. Shim,et al.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis , 2012, European Respiratory Journal.

[47]  Alimuddin Zumla,et al.  Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs. , 2012, The Journal of infectious diseases.

[48]  A. Diacon,et al.  Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[49]  M. Barer,et al.  Targeting Persisters for Tuberculosis Control , 2012, Antimicrobial Agents and Chemotherapy.

[50]  John P. Ray,et al.  Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections , 2012, Cell.

[51]  Stephen D. Bentley,et al.  Microevolution of extensively drug-resistant tuberculosis in Russia. , 2012, Genome research.

[52]  R. Wallis.  Biologics and infections: lessons from tumor necrosis factor blocking agents. , 2011, Infectious disease clinics of North America.

[53]  Lerato Mohapi,et al.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.

[54]  S. Vong,et al.  Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. , 2011, The New England journal of medicine.

[55]  Jian-Min Zhou,et al.  New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry , 2011, Clinical chemistry and laboratory medicine.

[56]  P. V. van Helden,et al.  Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment , 2011, Journal of Clinical Microbiology.

[57]  H. Schünemann,et al.  The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis , 2011 .

[58]  Richard G. White,et al.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update , 2011, European Respiratory Journal.

[59]  A. Diacon,et al.  Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[60]  A. Nunn,et al.  Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[61]  A. Diacon,et al.  Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  Arseny S Kaprelyants,et al.  Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. , 2011, Tuberculosis.

[63]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[64]  J. O’Grady,et al.  Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection , 2011, Tropical medicine & international health : TM & IH.

[65]  G. Drusano,et al.  The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model , 2010, mBio.

[66]  JoAnne L. Flynn,et al.  Understanding Latent Tuberculosis: A Moving Target , 2010, The Journal of Immunology.

[67]  A. Diacon,et al.  Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients , 2010, Antimicrobial Agents and Chemotherapy.

[68]  P. Sonnenberg,et al.  High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. , 2010, The Journal of infectious diseases.

[69]  W. El-Sadr,et al.  Timing of initiation of antiretroviral drugs during tuberculosis therapy. , 2010, The New England journal of medicine.

[70]  M. Barer,et al.  Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. , 2010, American journal of respiratory and critical care medicine.

[71]  S. Lawn,et al.  Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings , 2010, Current opinion in HIV and AIDS.

[72]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[73]  J. Flynn,et al.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.

[74]  T. Tupasi,et al.  Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. , 2009, American journal of respiratory and critical care medicine.

[75]  B. Abomoelak,et al.  A Novel In Vitro Multiple-Stress Dormancy Model for Mycobacterium tuberculosis Generates a Lipid-Loaded, Drug-Tolerant, Dormant Pathogen , 2009, PloS one.

[76]  S. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[77]  J. Blanchard,et al.  Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis , 2009, Science.

[78]  S. Gillespie,et al.  Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). , 2008, Tuberculosis.

[79]  R. Chaisson,et al.  Contribution of reinfection to recurrent tuberculosis in South African gold miners. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[80]  D. Mitchison,et al.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[81]  G. Maartens,et al.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. , 2007, The Journal of infectious diseases.

[82]  S. Waksman,et al.  Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. 1944. , 2005 .

[83]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[84]  T. Grossman,et al.  Inhibition of Antibiotic Efflux in Bacteria by the Novel Multidrug Resistance Inhibitors Biricodar (VX-710) and Timcodar (VX-853) , 2004, Antimicrobial Agents and Chemotherapy.

[85]  A. Nunn,et al.  Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial , 2004, The Lancet.

[86]  D. Minnikin,et al.  Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. , 2002, Microbiology.

[87]  N. Lounis,et al.  Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice , 2001, Antimicrobial Agents and Chemotherapy.

[88]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[89]  K. Eisenach,et al.  Quantitative Analysis of mRNA as a Marker for Viability of Mycobacterium tuberculosis , 1999, Journal of Clinical Microbiology.

[90]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.

[91]  R. Deitch.  Commentary from Westminster , 1984, The Lancet.

[92]  Mathur Kc.  Short term chemotherapy of tuberculosis. , 1984 .

[93]  A. Nunn,et al.  [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy]. , 1978, Bulletin of the International Union against Tuberculosis.

[94]  J. Mitchell.  Medical Aid for Vietnam , 1965, The Medical journal of Australia.

[95]  W. Fox,et al.  A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. , 1954, The Quarterly journal of medicine.

[96]  S. Waksman,et al.  Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.∗† , 1944, Clinical orthopaedics and related research.

[97]  E. Shorr,et al.  The Influence of Adverse Conditions upon the Respiratory Metabolism and Growth of Human Tubercle Bacilli , 1933, Journal of bacteriology.

[98]  R. Wallis,et al.  Sustainable tuberculosis drug development. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[99]  G. Schecter,et al.  Linezolid in the treatment of multidrug-resistant tuberculosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[100]  C. Peloquin.  What is the 'right' dose of rifampin? , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[101]  F. D’Acquisto,et al.  Anti-inflammatory activity of macrolide antibiotics. , 2000, The Journal of pharmacology and experimental therapeutics.

[102]  P. Butcher,et al.  Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. , 1998, FEMS microbiology letters.

[103]  A. Kochi,et al.  Tuberculosis: a global overview of the situation today. , 1992, Bulletin of the World Health Organization.

[104]  D. Siegler,et al.  Pulmonary tuberculosis , 1951 .

[105]  Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. , 1974, Lancet.

[106]  Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. , 1972, Lancet.